The investigational new drug application submitted by Fate Therapeutics for its off-the-shelf stem cell therapy FT516 to treat hematologic cancers has been accepted by the FDA. An early-stage trial will be launched to evaluate the therapy's safety and tolerability, and patients with treatment-resistant blood disorders will be administered three weekly doses.
Fate gains FDA's OK to initiate trial for blood cancer cell therapy
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.